Pediatrics · Tarzana, CA
NPI
1811902786
Since 2006
Specialty
Pediatrics
Code 208000000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
18370 Burbank Blvd, Suite #204
Tarzana, CA, 91356
Phone (818) 345-7792
Groups this clinician bills Medicare through
Medicare paid, 2024
$22K
241 services
Medicare patients, 2024
57
Average age 71
Drug cost, 2024
$405K
374 prescriptions
Company payments, 2025
$1,238
From 14 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Norman Lavin was code 99214 (office e&m - established), 190 times for 51 patients. In total Norman Lavin billed 241 services in 4 codes, and Medicare paid $22K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2008-02-07.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 190 | 51 | $99.14 | $19K |
By year: 2022 $32K for 261 services; 2023 $26K for 256 services; 2024 $22K for 241 services.
Medicare prescription drug claims, 2024
In 2024, the drug Norman Lavin prescribed most often to Medicare patients was Levothyroxine Sodium, with 90 prescriptions and refills. In total Norman Lavin wrote 374 Medicare prescriptions that cost $405K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 90 | 135 | 17 | $577 |
| Hydrocortisone Generic | 28 | 30 | Under 11 | $1,150 |
| Liothyronine Sodium Generic | 27 | 47 | Under 11 | $1,330 |
| Synthroid Levothyroxine Sodium | 25 | 49 | Under 11 | $1,743 |
| Genotropin Somatropin | 24 | 24 | Under 11 | $149K |
| Metformin Hcl Generic | 23 | 27 | Under 11 | $122 |
| Atorvastatin Calcium Generic | 16 | 26 | Under 11 | $60.4 |
| Metformin Hcl Er Metformin Hcl | 15 | 23 | Under 11 | $290 |
| Omnitrope Somatropin | 12 | 12 | Under 11 | $73K |
| Losartan Potassium Generic | 11 | 11 | Under 11 | $30.4 |
Brand drugs: 161 claims; generic drugs: 193 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Norman Lavin $1,238 ($1,238 in general payments such as food, travel and fees) from 14 companies. The largest payer was Ascendis Pharma Endocrinology Inc with $398.
| Company | Payments | Amount |
|---|---|---|
| Ascendis Pharma Endocrinology Inc ASND | 15 | $398 |
| Novo Nordisk Inc NVO | 13 | $155 |
| Tolmar, Inc. | 4 | $103 |
| Tandem Diabetes Care, Inc. TNDM | 5 | $101 |
| Pfizer Inc. PFE | 5 | $86.58 |
| Soleno Therapeutics, Inc. SLNO | 3 | $75.89 |
| Insulet Corporation PODD | 2 | $68.85 |
| Dexcom, Inc. DXCM | 3 | $59.87 |
| Sanofi-Aventis U.S. LLC SNY | 2 | $47.09 |
| Kyowa Kirin, Inc. 4151.T | 2 | $36.15 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.